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Abstract
The diagnosis of Bipolar Spectrum Disorders (BSD) given for office visits has risen 40 fold for
children and has risen dramatically for adults as well. Some of the growth may have been fueled
by re-categorization of individuals who would previously have received diagnoses of major
depression along with the widening of diagnostic criteria for BSD. Concomitant with the rise in
BSD diagnoses, the number of adults and children receiving atypical antipsychotics has
increased dramatically. Recent evidence finds that atypical antipsychotics cause considerable
reduction in brain volume. It is thus imperative to ensure that those with diagnoses comprising
BSD—Bipolar I, Bipolar II, and Bipolar Not Otherwise specified (NOS)—actually share a
common etiology and are being appropriately treated. This paper reviews the history,
evidentiary support, and implications associated with the expansion of the Bipolar Spectrum.
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Can a Diagnosis Be Epidemic,
with Therapeutic Efforts the Catastrophe?
In the years from 1999 to 2003, the diagnosis of bipolar given in office visits has
increased 40 fold for children. Bipolar Disorder diagnoses have increased during the same time
period for adults as well rising from 4.77% of office visits to 6.28% of office visits (Moreno et
al., 2007).
Allen Frances (2009), the Chairperson of the DSM-IV, has suggested that the sharp rise
in bipolar diagnoses is attributable to the manner in which criteria for the disorders were
written—that it was an issue of taxonomy rather than epidemiology. Obviously, diagnostic
criteria have profound implications for who is diagnosed, at what age, and whether they are
treated with psychotropic medications. Because psychotropic medications carry substantial
risks—if not guarantees—of side effects, those decisions must be judicious, and ever cognizant
of Hippocrates’ admonishment: First, do no harm. This review constitutes an audit of
psychiatry’s books, asking if they balance when the substantial risk of harm from such diagnoses
and the regimen of medication they entail is taken fully into account.
Creation of the Bipolar Spectrum
Over the years, those behaviors categorized under the bipolar label have expanded
greatly. In the DSM-II (Association, 1968), manic-depression, listed under the heading
“affective psychoses”, was the only bipolar type diagnosis. With subsequent editions of the
DSM, new categories of affect perturbations were included in manuals. The DSM-III
(Association, 1980) provided descriptions of the behaviors required to meet criteria for mixed
and manic episodes. The DSM-III-R (Association, 1987) added criteria for hypomania
(specified in the next paragraph). The literature recognized that some persons who had
experienced an episode of depression did have periods when they were enthusiastic, energetic,
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and animated to the extent that they met criteria for hypomania. Kupfer, Carpenter, and Frank
(1988) had argued that such individuals, who were labeled Bipolar II, should be viewed as
experiencing a variant of major depression. Dunner (1993) disagreed, arguing that since in
family studies both probands with bipolar I and probands with bipolar II reported more family
members with bipolar than did probands with major depression, bipolar II should be designated
as a bipolar disorder. With the 1994 publication of the DSM-IV, the diagnosis of bipolar II was
officially included in the manual under the heading of bipolar disorders.
The conventions for diagnosing bipolar spectrum disorders have basically been in effect
since 1994. The diagnosis of bipolar I as defined in the DSM-IV-TR (Association, 2000)
requires an episode of mania or a mixed episode. Mania criteria are comparatively restrictive,
requiring one week of “elated, expansive, or irritable mood” with three or more of the following
(or four or more of the following if irritable rather than expansive mood is present): inflated
self-esteem, decreased need for sleep, pressured speech, flight of ideas/racing thoughts,
distractibility, increased goal-directed activity, excessive involvement in risky but pleasurable
activities. The episode must cause marked impairment in occupational activity or in
interpersonal relationships.

In contrast to bipolar I, bipolar II requires having experienced an

episode of major depression and an episode of hypomania. Hypomania requires only four days
of an elevated or irritable mood with the same number of symptoms from the above list, but with
the caveat that none of the behaviors is severe enough to disrupt functioning. The need for
hospitalization or psychotic features precludes a diagnosis of hypomania. Those persons
exhibiting hypomania for less than four days can be diagnosed as bipolar not otherwise specified
(NOS).
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With the publication of the DSM-V soon approaching, arguments have been advanced for
broadening the bipolar spectrum even further, adding recurrent depression without hypomania
(Benazzi, 2002), irritability (Benazzi & Akiskal, 2005); agitated depression (Akiskal et al., 2000;
Benazzi, Koukopoulos, & Akiskal, 2004) and borderline personality disorder (Mackinnon &
Pies, 2006; Smith, Muir, & Blackwood, 2005). Even without a further loosening of diagnostic
criteria, Akiskal et al. (2000) estimates that half of those now carrying diagnoses of major
depression will be recast as bipolar. Studies tracking persons diagnosed with major depression
over time are consistent with this estimate (Angst, Sellaro, Stassen, & Gamma, 2005; Goldberg,
Harrow, & Whiteside, 2001). Zimmerman et al. (2009) in a study of a community sample of
2103 persons between the ages of 16 and 21 found that of the 23% of the sample meeting criteria
for major depression, 41.4% displayed features of bipolar. In the recently published BRIDGE
study (Angst et al., 2011), between 45.7 to 48.3% of those meeting criteria for major depression
also exhibited “a bipolarity specifier criteria”. If it can be assumed that half of persons who have
experienced an episode of major depression can be more accurately diagnosed as bipolar, then
the prevalence of bipolar in the population will be high indeed. Kessler et al. (Kessler et al.,
2005) find that the prevalence of major depression is 23.3%, consistent with the estimate in the
Zimmerman et al. study. If half of these individuals exhibit features of bipolar, potentially
11.6% of the population will be rebranded as bipolar.
The studies documenting a rise in the diagnosis of bipolar disorder in adults did not
breakout which particular Bipolar Spectrum disorders were being counted. However, over the
various DSM publications, the prevalence of bipolar I has remained relatively stable: both DSMIII (1980) and DSM-III-R (1987) indicate 0.4-1.2%; DSM-IV (1994) and DSM-IV-R (2000)
indicate 0.4-1.6%. Although definitive conclusions cannot be drawn from the Moreno et al.
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study, the expansion of individuals who are being labeled as exhibiting a bipolar spectrum
disorder (BSD) may be attributable to the addition of hypomania as a diagnostic criterion. The
addition of the new category is what has changed over editions of the manual. It is important to
ask whether mania and hypomania reflect the same underlying etiology and therefore are
appropriately treated in the same way. A related question concerns whether hypomania carries
any predictive import for subsequent emergence of mania.
Evidence Suggesting Bipolar I and Bipolar II
Share an Underlying Condition
A study by Shen et al. (2008) was interpreted as offering support for bipolar II being part
of the same continuum as bipolar I. College students meeting criteria for bipolar not otherwise
specified or bipolar II were tracked over a 33 month follow-up period. During this follow-up
period, 9.4% of the 149 persons with BPII and 3.5% of the 57 Cyclothymic/BP-NOS group
converted to mania while none of the normal controls experienced a manic episode.
The findings from this study deserve further scrutiny. Retrospective reports of adults
with bipolar I disorder indicate that depressive symptoms are more often reported as precursors
to the emergence of mania than are hypomanic symptoms (Calabrese et al., 2006). Moreover, if
a young person meets criteria for major depression, the probability of a manic episode is even
higher. When hospitalized young persons with depression (mean age of 23 in the study) were
followed by Goldberg et al. (2001) for 15 years, an episode of mania occurred in 19% of the
cases.

All of the Shen et al. research participants with Bipolar Spectrum diagnoses had met

criteria for major depression. Thus, depression, as opposed to hypomania, might have been the
relevant risk factor driving the conversion to mania. Shen et al. did not include a sample of those
who had experienced only an episode of major depression, so a comparison of whether major
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depression or hypomania constituted a stronger predictor was not possible. Further, the authors
did not analyze whether recurrent symptoms of depression or symptoms of hypomania were
better predictors of subsequent mania.
It is also important to ask about the criteria used to identify manic attacks in the Shen et
al. study. Do responses to a check list of symptoms, obtained in an interview, designate the same
population as does more stringent criteria for manic episodes such as hospitalization or
commitment to a state institution? The severity of the mania experienced by the college students
in meeting criteria for mania was not reported; although Shen et al. indicated that 3.4% of the
sample was hospitalized, which might have included hospitalization for depression. Moreover,
the authors did not analyze whether antidepressants treatment was related to the experience of
mania. Twenty of the 206 research participants in the Shen et al. study were receiving SSRIs,
which can precipitate mania in as many as 44% of those who exhibit fluctuations in mood
(Akiskal, Djenderedjian, Rosenthal, & Khani, 1977). In another publication, Alloy et al.
(2009a, p. 468) acknowledged that their findings needed replication in samples with more severe
Bipolar I. Findings from a study by Coryell et al. (1995), did examine whether bipolar II is a
predictor of bipolar I and will be discussed in the next section.
Evidence Suggesting Bipolar I and Bipolar II Are Not
Variants of the Same Underlying Condition
There is good reason to believe that bipolar I and bipolar II have distinct etiologies. First,
in some genetic studies, candidate genes found to distinguish those with bipolar I fail to
distinguish those with bipolar II and conversely those alleles distinguishing bipolar II are not
identified for bipolar I. In reviewing studies, Vieta and Suppes (2008) conclude, “in summary,
from the genetics perspective, most investigators tend to think that bipolar II breeds true (p.
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166).” Second, in family association studies, probands with bipolar I tend to have relatives with
bipolar I and probands with bipolar II tend to have relatives with bipolar II (Andreasen et al.,
1987; Benazzi, 2004; Coryell, Endicott, Reich, Andreasen, & Keller, 1984; Coryell et al., 1989;
Joyce et al., 2004). There have been a few exceptions to these findings. In the Joyce study
(Joyce et al., 2004), having the same diagnoses in families as the probands was found only in
relatives over 45. Both Heun and Maier (1993) and Gershon et al. (1982) found some elevation
in bipolar I diagnoses in relatives of persons with bipolar II compared to persons without
psychiatric diagnoses.
A third reason for believing that bipolar I and bipolar II are distinct is that people tend to
stay in their diagnostic category over time. Coryell et al. (1995) tracked patients for 10 years.
Few patients with bipolar II moved across categories. In fact, persons diagnosed with bipolar II
were not any more likely to develop mania than were patients with diagnoses outside the bipolar
spectrum. Coryell et al. concluded that bipolar II “is probably not simply a variant of bipolar I
disorder or of nonbipolar disorder, but is a separate and autonomous disorder (p. 389).” The
Shen et al. (2008) study of college students found evidence for conversion to mania in those with
bipolar II. We have to compare the relative merits of a 10 year study with diagnosed clinical
patients that did not find evidence of a crossover with a three year study with a non-clinical
sample of college students responding to check-lists that did find supporting evidence.
Questionnaires can be very helpful devices, and college students rewarding subjects, when, for
example, personality variables are being explored. However, when asking about the natural
history of disease processes, clinical samples offer more confidence that the observed
phenomenon represents true pathology.
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The final argument for bipolar I and bipolar II being distinct entities comes from
longitudinal findings of persons with these diagnoses. In the 13 year follow-up study of persons
with bipolar I and bipolar II by Judd et al. (2003), the data suggested that the disorders follow
different courses. Persons with bipolar II followed a more chronic course, although the manic
episodes of the persons with bipolar I were more severe. More of the persons with bipolar I
(63.3%) returned to their previous level of functioning between episodes than did the persons in
the bipolar II group (47.5%). The rate of anxiety disorder was higher than the general population
in the bipolar II group which was not the case in the bipolar I group. Judd et al. (2003) did not
take a position on whether their data supported bipolar I and bipolar II representing separate
entities. They did suggest that the issue would be resolved when the alleles of genes mediating
the disorder were identified. They agreed with the previously referenced position taken by Vieta
and Suppes (2008),that at the present time, genetic studies favored the distinct entity point of
view.
Hypomania is used as a criterion for a diagnosis of bipolar II. Unfortunately, the use of
hypomania as a diagnostic criterion has also helped to obfuscate the diagnosis in children. It has
fueled the explosion in the increase of children who are being diagnosed as pediatric bipolar. Its
diagnostic use has been the linguistic bridge connecting bipolar I to bipolar II, the latter then
being assumed to have an early form, pediatric bipolar. Without hypomania as a diagnostic
criterion for bipolar II, pediatric bipolar would probably not be possible as a diagnostic category,
because the natural history of classic bipolar suggests the disorder characteristically does not
begin until late adolescence at the earliest.
Pediatric Bipolar
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Prior to 1990, there was wide agreement that bipolar disorder did not manifest in young
children (Anthony & Scott, 1960; Goodwin & Jamison, 2007; Loranger & Levine, 1978). An
article by Carlson (1990) suggested that in some children bipolar disorder might emerge at a
young age. Similar speculation followed in an article by Werry, McClellan and Chard (1991).
Then in 1996, Biederman and colleagues published their findings that many children meet the
behavioral criteria listed in the DSM for bipolar disorder. They noted the strong co-morbidity
with attention deficit disorder hyperactivity and conduct disorder (Biederman et al., 1996). In
1996, bipolar disorder was the least frequent diagnosis for hospitalized children in the United
States; by 2004, it was the most frequent diagnosis (Blader & Carlson, 2007). Issac (1995)
claims that 50% of children receiving in-patient psychiatric treatment meet criteria for bipolar
disorder.
What is surprising about the diagnosis of pediatric bipolar is the divergence from the
previously assumed portrait of persons with bipolar I. Akiskal et al. (2000) describes the typical
patient with bipolar as “warm, people-seeking or extroverted” and “articulate and eloquent” (p.
s12). Children with pediatric bipolar exhibit poor social skills, often have few friends, are often
teased (Geller et al., 2000) and achieve low scores on measures of social functioning and school
achievement (Tillman et al., 2003). Adults with bipolar I disorder experience episodes of mania
with the typical episodes lasting six weeks to six months (Biederman, Klein, Pine, & Klein,
1998; Goodwin & Jamison, 2007). Indeed for Kraepelin (1899, p. 269) the distinction between
those with bipolar and those with schizophrenia was that between episodes those with bipolar
were well functioning whereas the schizophrenics exhibited a deteriorating course. In contrast to
adults with bipolar I, the children with pediatric bipolar studied by Geller’s group experienced
mania lasting on average 3.6 years (Craney & Geller, 2003; Tillman et al., 2003). Birmaher et
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al. (2009a) report a mean duration of 123.7 weeks for the index episode. Finally, as previously
mentioned, retrospective reports of well characterized persons with bipolar I concluded that their
first episode of mood disorder was more often at the depressed pole and age of onset averaged 17
(Calabrese et al., 2006; Perlis et al., 2004). In children with pediatric bipolar, they are likely to
display mania as preschoolers (Geller et al., 2000).
Youngstrom, Freeman, & Jenkins (2009) suggest that confidence in a childhood
diagnosis of pediatric bipolar is increased if the parent also meets criteria for bipolar disorder.
There is broad consensus that bipolar disorder is hereditary (Goodwin & Jamison, 2007, p. 41).
Not surprisingly, the exponents of the legitimacy of the pediatric bipolar diagnosis have
conducted studies examining the parents of children meeting criteria for bipolar disorder. They
do find that a large number of parents meet criteria for bipolar disorder as well as meeting
criteria for major depression, anxiety disorders, substance abuse and early onset of diverse
symptomatology. Unfortunately, the studies do not specify whether the parents meet criteria for
bipolar I or bipolar II; whether they exhibit any of the classic symptoms of bipolar I (spending
sprees, grandiosity, hallucinations); or whether the parents’ symptomatology ever became a
focus of attention for others (Borchardt, Bernstein, & Crosby, 1995; Endrass et al., 2007;
Faraone, Biederman, Mennin, Wozniak, & Spencer, 1997; Findling et al., 2005; Geller et al.,
2006; Wozniak, Biederman, Mundy, Mennin, & Faraone, 1995). We can conclude from these
studies that children share many behaviors with their parents. Whether the children or the
parents share the same underlying etiology as classical bipolar I has not been established.
Many studies have been published examining the children of parents with bipolar
diagnoses. The largest sample was studied by Birmaher et al. (2009b). Here again, the children
were not divided according to type of bipolar disorder in the parent. Birmaher et al. found that
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10.6% of the children met criteria for a bipolar spectrum disorder with 68% of these children
reaching criteria for bipolar-not otherwise specified. The studies examining children of parents
with bipolar disorder were recently reviewed (Littrell & Lyons, 2010). The findings from the
studies varied according to whether they were published prior to 1990, or they were recently
published, when the concept of bipolar II became more prominent. Early studies found relatively
low rates (5%) of disruptive behavior and attention deficit hyperactivity disorder in children of
parents with bipolar (Akiskal et al., 1985; Klein, Depue, & Slater, 1985; Laroche et al., 1987;
Radke-Yarrow, Nottelmann, Martinez, Fox, & Belmont, 1992). Similarly, reviews from this
period concluded that symptoms of depression were the most prominent finding (Goodwin &
Jamison, 2007; Lapalme, Hodgins, & LaRoche, 1997). As studies began to include more
children of parents with bipolar II, researchers noted a higher prevalence of ADHD, conduct
disorder, and disruptive behavior (Chang, Blasey, Ketter, & Steiner, 2003; Hodgins, Faucher,
Zarac, & Ellenbogen, 2002).
Duffy, Alda, Hajek, and Grof (2009) recently published the findings of the children of
parents with well characterized bipolar I. The children in Duffy et al.’s sample conform to the
previously assumed portrait of persons with bipolar: the first mood episode occurred at a mean
age of 17 with none of the children meeting criteria for a DSM disorder prior to 12; episodes of
depression lasted an average of 6.1 months and episodes of mania lasted an average of 1.7
months; the first episode of mood disorder was most frequently major depression. Moreover,
with regard to the characterization of the first episode, Duffy et al’s findings were very similar to
those of Akiskal et al.’s (Akiskal et al., 1985) earlier longitudinal study of children of parents
with bipolar I, from which the authors concluded, “bipolar disorder often begins insidiously in
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late childhood, adolescence, and early adulthood with relatively minor oscillations in mood, most
characteristically depressive in nature (p.1002)”.
In psychiatry, proposals of other ways to categorize children displaying affective
symptoms are available. Leibenluft (2011) reviewed the literature following children exhibiting
chronic irritability. She has been an exponent of labeling children with continual, non-episodic
irritability and disruptive behavior as severe mood dysregulation, although recognizing that these
children currently are frequently diagnosed as pediatric bipolar disorder. Studies by Brotman et
al.(2006) and Stringaris, Cohen, Pine, and Leibenluft (2009) found that continuous irritability
predicted adult depression and anxiety and not the bipolar pattern. Moreover, those children
with chronic irritability do not respond to treatment with lithium (Dickstein et al., 2009). With
an alternative diagnosis, the rates of pediatric bipolar may decline.
It is beyond the scope of this article to discuss the various possibilities for classifying
children who exhibit dysregulation in mood being considered by the DSM-V Mood Disorders
Work Group (Workgroup, 2011). However, it is noted that the DSM Childhood and Adolescent
Disorder Work Group has proffered the terminology of temper dysregulation disorder with
dysphoria as an alternative to severe mood dysregulation (Workgroup., 2011). The workgroup
has noted that alternative terminology could reopen the question of appropriate treatment for
children currently labeled bipolar as “current convention renders treatment with antidepressants
or stimulants relatively contraindicated without concurrent mood stabilizers or antipsychotics (p.
6)”.
Creating Confusion
The combining, in some research, of the various categories aggregated together under the
bipolar spectrum has not been helpful. In particular, the sharing of the term bipolar, in bipolar I
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and bipolar II, implies a closer association between the two diagnoses than has been justified by
empirical evidence. Specific confusion has been created by sometimes aggregating data from
both persons with bipolar I and bipolar II, or not even making a distinction between the two.
This could explain many of the inconsistencies in the published data.
Prior to the liberal use of the concept of hypomania in association with bipolar II, the
modal picture of manic illness was relatively well defined. It was episodic with major
depression occurring first. It was rare for disorder to be diagnosed before age 17 (DSM-III-R,
1987; Calabrese et al., 2006) . With the advent of bipolar II and the elevation of energetic and
enthused behavior to a medical label of hypomania, these historically received views have been
challenged. When criteria are changed, beliefs about natural history get revised. The big issue is
whether bipolar I and bipolar II share a common etiology. As the studies reviewed here suggest,
there is little empirical support for a common etiology; in fact, the bulk of the evidence supports
the opposite conclusion. Yet the assumption that they are manifestations of a common brain
mechanism has probably contributed to the explosion of antipsychotic medications.
The Rise in the Use of Atypical Antipsychotics
Atypical antipsychotics include risperidone, olanzapine, quetiapine, ziprasidone,
clozapine, aripiprazole, paliperidone, as well as others. They are referred to as second generation
antipsychotics. The first of the class, clozapine, was approved by the FDA for the treatment of
schizophrenia in 1989. Others followed. The use of atypicals has accelerated rapidly since their
introduction into the market. Domino and Swartz (Domino & Swartz, 2008) compared the
period of 1996-1997 to 2004-2005 among outpatients receiving psychiatric care. They reported
that in the earlier period 0.72% of the non-institutionalized persons in the population were
prescribed atypical whereas in 2004-2005, l.17% of the non-institutionalized person in the U.S.
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received atypicals. The percentage of schizophrenics being treated with atypicals remained
roughly the same across the two periods. The increase was accounted for by the increased use of
atypical antipsychotics for treatment of mood disorders. Whereas in the earlier period, 18% of
those with a mood disorder received atypicals, in the later period 35% of those with a mood
disorder received an atypical. Moreover, more youth are being treated with the atypicals, rising
from 0.2% to 0.7% of American youth. Consistent with these figures, Crystal, Olfson, Huang,
Pincus, and Gerhard (2009) found that from 1996 to 2006, antipsychotic treatment rates
escalated from 0.21% to 0.90% of privately insured children in the United States. The rates were
even higher for children in state Medicaid programs, rising from 2.7% in 2001 to 4.2% in 2004.
Mojtabai and Olfson (2010), looking at office-based psychiatry from 1996 to 1997, documented
the increase in the practice of polypharmacy, e.g., prescribing an atypical antipsychotic with an
antidepressant. Blanco, Laje, Olfson, Marcus, and Pincus (2002) documented the increase in the
use of atypical antipsychotics and valproate and the decline in the use of lithium in the treatment
of bipolar disorder from 1992 to 1999.
Cause for Concern
Ho et al. (Ho, Andreasen, Ziebell, Pierson, & Magnotta) followed first episode persons
with psychosis for a mean of 7.2 years, obtaining multiple high-resolution magnetic resonance
scans over time. They found that after controlling for severity of symptoms, higher use of
antipsychotics (both atypicals and older neuroleptics) was associated with brain tissue loss.
While they noted that causal inference is not possible without random assignment and a control
group, their findings are consistent with the results of studies examining the impact of
antipsychotic medication in macques. The animal studies did observe random assignment and
did have a control group. Konopaske et al. (2008) found a 20.5 percent reduction in astrocyte
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numbers and Konopaske et al. (2007) reported a 11.8-15.2% reduction in gray matter volume in
the left parietal lobes. Moreover, antipsychotics do impair cognitive function in the short term in
humans (Frangou, Donaldson, Hadjulis, Landau, & Goldstein, 2005). While Ho et al. did not
speculate on the mechanism behind lack of dopamine signaling and brain volume, there is a
voluminous literature on growth factors released from glial cells being critical to maintain the
health of the brain (Schwartz & Schechter, 2011; Ziv & Schwartz, 2008). Dopamine can induce
astrocyte cells to release growth factors (Miklic, Juric, & Carman-Krzan, 2004). Reflecting on
the strong possibilities that dopamine antagonists reduce brain cortex, Ho et al. raised the issue
of cost-benefit analysis in the use of antipsychotics for those with affective disorders.
Other side effects of atypical antipsychotics are not trivial. The Clinical Antipsychotic
Trials of Intervention Effectiveness found that the atypicals are associated with movement
disorders, although perhaps movement problems are less likely than with the older neuroleptics
(Casey, 2006; Manschreck & Boshers, 2007; Miller et al., 2005). In children, reports of tardive
dyskinesia with atypicals have been reported (Woods, Martin, Spector, & McGlashan, 2002)
and, in children, extrapyramidal symptoms with atypicals are more pronounced (Sikich, Hamer,
Bashford, Sheitman, & Lieberman, 2004; Tohen et al., 2007). The atypicals are, however, most
notorious for inducing weight gain (which fails to plateau), dyslipidemia, and diabetes (Ghaemi,
2008; Goodwin & Jamison, 2007).
Other pharmacological interventions for bipolar include lithium and anticonvulsant drugs.
Major concerns for lithium are the kidney damage and thyroid gland dysfunction (Bendz, Aurell,
& Lanke, 2001; Goodwin & Jamison, 2007; Markowitz et al., 2000). For those treated for more
than 12 years, 50% of patients exhibit impaired renal concentrating ability and 20% of patients
exhibit frequent urination. In a sample of 74 patients on lithium for an average of 20 years, 12
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reached End Stage Renal Disease (Presne et al., 2003). Even after lithium is discontinued,
kidney destruction can continue (Markowitz et al., 2000). Lithium also impairs cognitive
function (Ghaemi, 2008; Silva et al., 1992).
Anticonvulsant drugs include valproate, lamotrigine, and carbamazepine. Both valproate
and carbamazepine can induce depression (Boylan, Devinsky, Barry, & Ketter, 2002), and the
FDA has issued a warning regarding suicidal ideation with these drugs (Administration, 2007,
2008). All the anticonvulsants disrupt cognitive functioning. There are also specific effects on
other organs with these drug (Goodwin & Jamison, 2007; Loring & Meador, 2004).
Treatment of depression observed in persons carrying bipolar diagnoses has long been
controversial. Antidepressant drugs are believed to induce rapid cycling, although exact
prevalence may only be 20% (Benazzi, 2007; Ghaemi, Hsu, Soldani, & Goodwin, 2003). Of
greater concern is the FDA warning of induction of suicidality in those with bipolarity when
treated with antidepressants (Administration, 2007).
Case for early treatment. Kiki Chang and others (Chang, Howe, Gallelli, & Miklowitz,
2006; Chang & Kowatch, 2007; Chang, 2010) have been advocates of early medication of
pediatric bipolar in order to prevent the emergence of full blown bipolar disorder. Their
assumption is that experiencing extremes of affect operates as a kindling mechanism. The
kindling hypothesis is based on the observation that giving a small amount of electrical
stimulation to an animal over time will eventually elicit a seizure at a dose which would not
provoke a seizure in a naïve animal. Post (2007) suggested that the course of bipolar disorder is
analogous to the process of kindling in producing seizures. The experience of affective episodes
changes the brain in a way that would make the occurrence of subsequent episodes more likely.

Bipolar 18

The hypothesis that more episodes of affective disorder will cause more extreme or more
frequent later episodes has been criticized. It is true that duration of wellness intervals between
episodes is inversely correlated with total number of episodes during the life-time (Goodwin &
Jamison, 2007, p. 128). However, these findings do not necessarily imply that episodes cause a
greater degree of subsequent illness. Slater (1938) as translated by Oepen et al. (Oepen,
Baldessarini, Salvatore, & Slater, 2004) cautioned that persons with short cycles will have more
episodes whereas those with long cycles will have fewer episodes. Aggregating across
individuals will yield an inverse relationship between number of episodes and duration of
wellness intervals. One must examine whether the duration of wellness shortens with the ordinal
value (first, second, third) for the individual to discover whether an episode will increase the
length of a subsequent episode. Goodwin and Jamison (2007, p. 152) concluded there is no
consistent evidence that periods of wellness decrease as a function of the ordinal value of the
episode. Moreover, Goodwin and Jamison (2007, p. 129) concluded that after the first three
episodes, the frequency of subsequent episodes is fairly constant. This was consistent with the
Duffy et al. (2009) observations in those children of well characterized parents with bipolar I
who developed their own bipolar disorder. There was no evidence of shortening of wellness
periods across the first three observed episodes.
With regard to early pharmacological treatment changing the course of the disorder, the
evidence is against early treatment altering the course. Baldessarini et al. (2007) in a study of
764 adults, found that whether latency of treatment was measured as number of prior episodes or
time to seek treatment after initial emergence of symptoms, latency did not relate to percentage
of time spent ill during treatment or the need for hospitalization. Baldessarini et al.’s findings
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were consistent with an earlier meta-analysis of 11 published studies involving over 1458
individuals (Baethge et al., 2003).
Outcomes before psychotropics compared to current outcomes: The difference a
drug makes. Studies evaluating the efficacy of psychotropic medications tend to be short term
(Oldham, 2011). For example, Geddes, Burgess, Hawton, Jamison, & Goodwin (2004) review
of “long-term” lithium therapy examined studies with follow-up of two years. Winokur et al.
(1994) conducted a naturalistic study with an unusually long follow-up period of ten years.
Interestingly, in the Winokur et al. study, the authors concluded “treatment intensity was not
related to decreasing episodes or to changes in cycle length”. Nevertheless, for addressing
questions regarding long term efficacy of pharmacotherapy, current outcomes with medications
can only be contrasted with the pre-drug treatment outcomes.
Perhaps the most surprising contrast in the literature on treating persons with Bipolar
Disorder is the contrast in the outcome statistics for those treated before the emergence of
modern psychiatry. According to Kraepelin (1899, p. 115-116) there are patients who suffered
only one episode of mania requiring hospitalization. Rennie’s report (1942) on 208 patients
treated between 1913 and 1916 is similarly optimistic though different in details. Ninety percent
of patients recovered from their initial episode, while 21% never relapsed. Of the cases
experiencing relapse, 30% remained in remission for between 10 to 20 years. Thus, 51%
exhibited long term recovery. Winokur, Clayton, and Reich (1969) reviewed early studies and
concluded there “was no basis to consider manic depressive psychosis permanently affected
those who suffered from it (p.21)”.
Outcomes from earlier studies stand in sharp contrast to the findings reported for adult
bipolar patients in later years. Harrow, Goldberg, Grossman & Meltzer (1990) found that 80%
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of those who recovered from an episode relapse within 1.7 years; 23% are continuously
unemployed and another 35% are erratically employed. Post et al. (2003) found that 62.8% of
persons experienced 4 or more mood episodes per year. Judd et al. (2002) followed persons with
bipolar I for 12.8 years assessing their status on a weekly basis. They found that adult patients
with bipolar I were symptomatic on average for 47.3% of the follow-up interval with only 2.1%
of the sample exhibiting low levels of symptoms. Some patients (9.6%) were symptomatic
during all of the weeks. Depressive symptoms occurred during an average of 31.9% of weeks;
manic symptoms occurred during an average of 8.9% of weeks; and mixed states occurred
during an average of 5.9% of weeks.
Scant data are available regarding the outcome of bipolar II disorder prior to the advent
of psychotropic medications because the diagnosis did not exist before the drug era. Persons
with bipolar II would probably be classified as depressed. Questions have been raised regarding
whether antidepressant treatment contributes to chronicity in depression (Fava, 2003; Fava &
Offidani, 2010).
The previously cited study by Judd et al. (2003) suggested a more chronic course for
those with bipolar II than those with bipolar I. This outcome is particularly surprising given the
findings on the personality characteristics of those individuals who meet criteria for bipolar II.
Alloy et al. (2009a) found that college students with bipolar II are more likely to exhibit elevated
scores on the Carver and White measure of the behavioral activation system (BAS) (Carver &
White, 1994). Moreover, if students are selected for extreme scores on the BAS and compared
to those with moderate scores, the former more often meet criteria for bipolar II (Alloy et al.
2006). There is an extensive literature on the behavioral activation system. Contrary to
dysfuction, the general literature on the BAS (as measured by EEG asymmetry or scores on self-
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report measures), suggests that having a strong behavioral activation system confers resilience in
the face of stress (Davidson, 1998). Those who exhibit stronger left frontal brain activity,
another measure of a strong behavioral activation system, are less responsive to negative events,
and more responsive to positive stimuli (Davidson, 1998; Harmon-Jones & Allen, 1997; Jackson
et al., 2003; Sutton & Davidson, 2000). Those who exhibit stronger left brain activity are less
prone to depression (Davidson, 1998). If they do become depressed, high BAS sub-scale scores
predict shorter duration of the depressive episode (Kasch, Rottenberg, Arnow, & Gotlib, 2002).
Tomarken and Davidson (1994) found that repressors are high on BAS measures and repressors
cope better with bereavement (Coifman, Bonanno, Ray, & Gross, 2007).

In the Alloy et al.

studies, although high scores on the BAS predicted hypomania, BAS scores were unrelated to
subsequent depressive symptoms (Alloy, Abramson, Urosevic, Bender, & Wagner, 2009b; Alloy
et al., 2008). Thus, hypomania, perhaps through its correlation with stronger BAS, may indeed
reflect resilience rather than a cause for concern.
Extending the bipolar label to those meeting criteria for bipolar II implies that hypomania
is an abnormal state, suggestive of illness. Benazzi (2007) acknowledges that hypomanic
episodes can be productive. Johnson (2005) reviewed the many studies suggesting that those
who experience hypomania are more successful in terms of occupational status than the general
population. But, according to Benazzi (2007), hypomania is often rapidly followed by
depressive episodes. Empirical support for this statement was based on a study by Benazzi and
Akiskal (2006) of the retrospective reports of 206 patients, 80% of whom had switched poles
rapidly, although the authors failed to analyze whether hypomania was quickly followed by
depression or the depression was followed by hypomania. Other researchers have examined
whether depression reliably follows extremes in positive mood (mania). Haag et al. (1987) failed
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to find a reliable pattern in whether depressive episodes followed manic episodes within a short
window of time or whether mania followed depression within a short window of time. Vieta et
al. (2009) found that a switch from mania into depression within in a 12 week period in a sample
of 2390 patients was a rare event (5.0%). Moreover, across studies, 25-33% of persons who
have experienced a manic episode never have an episode of major depression (Karkowski &
Kendler, 1997; Kessler, Rubinow, Holmes, Abelson, & Zhao, 1997). Studies examining whether
depressive symptoms follow shortly after hypomania are sparse. However, the finding that
periods of hypomania are common in non-clinical samples argues against hypomania operating
as a precipitant to depression (Udachina & Mansell, 2007; Wicki & Angst, 1991).
Questions are Being Raised
Presently, the American Psychiatric Association is deliberating those diagnostic
categories that will appear in the DSM-V. Allen Frances (2009), the Chair of the DSM-IV, has
publicly raised concerns about the “unintended consequences” of the DSM-IV which resulted in
an explosion of new cases of Autism, Bipolar, and ADHD. Frances is quoted by Gary
Greenberg (2010), in explaining why he was moved to become a crusader, as saying ,“kids
getting unneeded antipsychotics that would make them gain 12 pounds in 12 weeks hit me in the
gut.” Whereas Frances refers to unintended consequences of how criteria for various diagnoses
were written, others suggest that the rise in the numbers being diagnosed and being treated with
antipsychotics may have been intended. Senator Charles Grassley’s Committee has been
investigating the links between academic psychiatry and the pharmaceutical industry. Joseph
Biederman, the initiating force behind the pediatric bipolar diagnosis, was found to have failed to
report the extent of financial remuneration from the pharmaceutical industry(Harris & Carey,
2008). In a two part article followed by replies to letters in the New York Review of Books
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(2011), Marcia Angell, former editor of the New England Journal of Medicine, voiced concern
over the subjective nature of psychiatric diagnosis, the lack of studies on long term efficacy of
pharmacotherapy, and the influence of the pharmaceutical houses on academic medicine.
Robert Whitaker (2010), a journalist, has documented the rise in the numbers of persons
receiving disability on the basis of psychiatric diagnoses over the last several decades. Whitaker
contrasts outcomes for various psychiatric disorders prior to drugs for the various conditions to
the outcomes reported in the medication era. He accepts the arguments raised by others (Fava &
Offidani, 2010) that although drugs might provide temporary amelioration, in the long run they
may create a chronic course. In psychotropic drug studies, evaluation of efficacy occurs after 68 weeks (Jackson, 2005; Khan, Kolts, Thase, Krishnan, & Brown, 2004). Rarely are long-term
outcomes of the never medicated contrasted with the outcomes of those who receive long-term
treatment. Most of the drugs used to treat Bipolar Disorder impair cognitive function. In studies
evaluating the efficacy of particular drugs for various disorders, the impact on target symptoms
are evaluated. Rarely, are more general areas of functioning tested such as the ability to
concentrate, calculate, or follow a complex argument. As important as a tranquil mood can be to
daily function, these other capacities can be seen as equally integral to a person’s successful
functioning. Cognitive capacity is particularly important in small children who must master a
great deal of material in school if they are to become productive citizens. Given the complexity
of modern society and the demands to maintain a competitive workforce in the world, perhaps
we need to question whether through irresponsible over-diagnosis and automatic medicating, we
are in danger of producing an impaired generation.
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